Haemonetics HAE
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 78th percentile, 5-year average 42.1x
#2624 of 2994 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 98th percentile, 5-year average 4.5x
#4602 of 5331 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 98th percentile, 5-year average 3.1x
#3680 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 6.23 | – | 4.47 | 98% (pricier than usual) | #4602 of 5331 (1 = cheapest) |
| PE | 54.40 | 27.47 | 42.15 | 78% (pricier than usual) | #2624 of 2994 (1 = cheapest) |
| PS | 4.05 | 3.70 | 3.08 | 98% (pricier than usual) | #3680 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on HAE.
Sign in to join the discussion.